


## Azide-PEG4-VC-PAB-Doxorubicin

<b>Cat. No.:</b>	HY-136288		
<b>Molecular Formula:</b>	C <sub>57</sub> H <sub>75</sub> N <sub>9</sub> O <sub>21</sub>		
<b>Molecular Weight:</b>	1222.25		
<b>Target:</b>	Drug-Linker Conjugates for ADC		
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (81.82 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	0.8182 mL	4.0908 mL	8.1816 mL
5 mM	0.1636 mL	0.8182 mL	1.6363 mL
10 mM	0.0818 mL	0.4091 mL	0.8182 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Azide-PEG4-VC-PAB-Doxorubicin is a agent-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody agent conjugate (ADC)<sup>[1]</sup>. Azide-PEG4-VC-PAB-Doxorubicin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

#### IC<sub>50</sub> & Target

Daunorubicins/Doxorubicins

### REFERENCES

[1]. Hayward R, et al. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 2007 Jul;46(4):20-32.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA